期刊文献+

强直性脊柱炎的诊断与治疗骨科专家共识 被引量:47

原文传递
导出
摘要 一、概述 强直性脊柱炎(ankylosing spondylitis.AS)是一种结缔组织疾病.主要侵犯骶髂关节、脊柱关节、椎旁软组织及外周关节.可伴发关节外表现,严重者可发生脊柱畸形和关节强直。据初步调查,我国AS的患病率约为0.3%,男女之比约为2~3:1.女性发病较缓慢且病情较轻。发病年龄通常在13~31岁.高峰发病年龄为20-30岁,40岁以后及8岁以前发病者少见。
出处 《中华骨科杂志》 CAS CSCD 北大核心 2012年第9期895-898,共4页 Chinese Journal of Orthopaedics
  • 相关文献

参考文献22

  • 1强直性脊柱炎诊断及治疗指南[J].中华风湿病学杂志,2010,14(8):557-559. 被引量:865
  • 2Rudwaleit M, Braun J, Sieper J. ASAS classification criteria for axial spondyloarthritis. Z Rheumatol, 2009, 68(7): 591-593.
  • 3Sieper J, Klopsch T, Richter M, et al. Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double- blind, controlled study. Ann Rheum Dis, 2008, 67(3): 323-329.
  • 4Song IH, Hermann K, Haibel H, et al. Effects of etanercept ver- sus sulfasalazine in early axial spondyloarthritis on active inflam- matory lesions as detected by whole-body MRI (ESTHER): a 48- week randomised controlled trial. Ann Rheum Dis, 2011, 70(4): 590-596.
  • 5van der Heijde D, Sieper J, Maksymowych WP, et al. 2010 Up- date of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis, 2011, 70(6): 905-908.
  • 6Takahiko H, Hiroki M, Terufumi S, et al. Transmembrane TNF- a:structure, function, and interaction with anti-TNF agents. Rhrumatology 2010;49:1215-1228.
  • 7Maksymowych WP. Update on the treatment of ankylosing spondylitis. Ther Clin Risk Manag, 2007, 3(6): 1125-1133.
  • 8Braun J, van den Berg R, Baraliakos X, et aL 2010 update of the ASAS/EULAR recommendations for the management of ankylos- ing spondylitis. Ann Rheum Dis, 2011, 70(6): 896-904.
  • 9Dougados M, Braun J, Szanto S, et al. Efficacy of etanercept on rheumatic signs and puhnonary function tests in advanced anky- losing spondylitis: results of a randomised double-blind placebn- controlled study (SPINE). Ann Rheum Dis, 2011, 70(5): 799-804.
  • 10Braun J, van der Horst-Bruinsma IE, Huang F, et al. Clinical ef- ficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. Arthritis Rheum, 2011, 63(6): 1543-1551.

二级参考文献41

  • 1邱贵兴,杨庆铭,余楠生,翁习生,王凯,李晓林.低分子肝素预防髋、膝关节手术后下肢深静脉血栓形成的多中心研究[J].中华骨科杂志,2006,26(12):819-822. 被引量:428
  • 2陆芸,马宝通,郭若霖,张建国,吴英华,庞贵根,辛景义,叶伟胜,邹玉安,王毅,董强,王学谦,Kerry H,Paul C,John F.骨科创伤患者深静脉血栓危险因素的研究[J].中华骨科杂志,2007,27(9):693-698. 被引量:244
  • 3Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, 126(3 Suppl): 338S-400S.
  • 4Mosby's Dictionary of Medicine, Nursing & Health Professions. 7th ed. St Louis, Mo: Mosby; 2006. 115-116. 335, 520, 1454, 1849, 1949.
  • 5陆慰萱,王辰.肺循环病学.第1版.北京:人民卫生出版社.2007.
  • 6O'Donnell M, Weitz JI. Thromboprophylaxis in surgical patients. Can J Surg, 2003, 46: 129-135.
  • 7Piovella F, Wang CJ, Lu H, et al. Deep-vein thrombosis rates after major orthopedic surgery in Asia: an epidemiological study based on postoperative screening with centrally adjudicated bilateral venography. J Thmmb Haemost, 2005, 3: 2664-2670.
  • 8Heit JA, O'Fallon WM, Petterson TM, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med, 2002, 162: 1245-1248.
  • 9Anderson FA, Spencer FA. Risk factors for venous thromboembolism. Circulation, 2003, 107(23 Suppl 1): Ⅰ9-16.
  • 10Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest, 2001, 119(1 Suppl): 132S-175S.

共引文献1184

同被引文献391

引证文献47

二级引证文献158

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部